Adding one drug to radiation cut the risk of prostate cancer spreading or death by 58%

For men whose prostate cancer is likely to come back after treatment, the fear is spread — metastasis. In new late-breaking results from the Australian and New Zealand Urogenital and Prostate (ANZUP) trials group, presented at the ESMO congress, adding the hormone-blocking drug darolutamide (Nubeqa) to standard hormone therapy and radiation cut the risk of metastasis or death by 58% compared with placebo. After a median follow-up of 3.8 years, 95% of men on the combination were free of spread at four years, against 88% on standard treatment alone, with a safety profile in line with earlier studies.

SDG 3 · Good health and well-being — Mechanism: tech innovation